Tempus Ai,Inc.(TEM) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for the core business increased by over 33% in 2025, with the acquisition of Ambry contributing to even higher growth [4] - The diagnostics business in oncology experienced a unit growth of 29%, with a remarkable 56% quarter-over-quarter growth in minimal residual disease (MRD) testing [4][5] - The licensing business, referred to as Insights, grew by 69% in the quarter, with a projected growth of approximately 40% for the upcoming quarter [5] - Net revenue retention stood at 126%, indicating strong customer loyalty and increased ordering from existing clients [5] Business Line Data and Key Metrics Changes - The diagnostics segment showed strong performance, particularly in oncology, with unit growth of 29% and hereditary testing holding steady at 23% [4] - The data business, which includes licensing and applications, is growing even faster, with total contract value exceeding $1.1 billion [5] - The MRD testing segment is highlighted as having significant growth potential, with only a small percentage of the sales force currently selling it [33] Market Data and Key Metrics Changes - The company is well-positioned in the healthcare AI market, leveraging over 450 petabytes of connected multimodal data to enhance its offerings [9][10] - The oncology market is experiencing healthy growth rates, with the company capturing additional market share due to its data advantage [41] Company Strategy and Development Direction - The company aims to integrate technology and AI into diagnostics, ensuring that decisions in clinical and research settings are data-driven [73] - The acquisition of Ambry was primarily to broaden the comprehensive nature of the testing compendium, aligning with the trend of providers seeking comprehensive solutions [60] - The company is focused on enhancing its data offerings and maintaining a competitive edge through proprietary data and technology [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, with guidance of $1.59 billion in revenue and approximately $65 million in positive adjusted EBITDA [5] - The company anticipates continued strong demand for its data products, indicating a unique position in the market [48] - There is an expectation of moderation in hereditary testing growth rates, while oncology remains robust [30] Other Important Information - The average selling price (ASP) for tests in Q4 was around $1,640, with expectations of reaching over $2,200 in the coming years [21] - The company is actively working on enhancing its tumor-naive assays to compete in the market, with a focus on improving performance [70] Q&A Session Summary Question: Concerns about AI and market competition - Management highlighted the unique position of the company in the AI space, emphasizing its proprietary data and technology advantages [9][10] Question: Strategic value of Paige Predict and ASP expectations - Management discussed the importance of contextualizing diagnostics and the expected ASP growth driven by FDA-approved versions of tests [15][21] Question: Update on foundation model development - Management confirmed that benchmarks for the foundation model have been met and that testing is ongoing with AstraZeneca [26] Question: Volume growth assumptions for oncology and hereditary testing - Management indicated strong growth in oncology and moderate expectations for hereditary testing, with a focus on high teens growth rates [30][29] Question: Insights on MRD testing and sales force effectiveness - Management noted the strong performance of MRD testing despite a constrained sales effort, indicating significant potential for future growth [33] Question: Changes to sales organization and investment priorities - Management stated that no major changes were made to the sales organization, with a focus on leveraging technology and AI for diagnostics [73]